We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+44.44%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$139M
AUM Growth
+$11.7M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 84.18%
2 Technology 15.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.9B
$70.9M 50.98%
4,409,991
DAWN
2
DELISTED
Day One Biopharmaceuticals
DAWN
$34.1M 24.51%
2,548,403
AEVA
3
Aeva Technologies
AEVA
$1.2B
$22M 15.82%
3,697,039
RLYB icon
4
Rallybio
RLYB
$84.5M
$11.8M 8.46%
257,464
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$315K 0.23%
37,051

Similar funds

Canaan Partners XI's Q1 2023 Portfolio in Review

As of Q1 2023, Canaan Partners XI held 5 positions worth $139M, up 9.2% from $127M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Canaan Partners XI opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Technology.

  • Canaan Partners XI's ten largest holdings make up 100% of its $139M portfolio in Q1 2023.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q1 2023.
  • Canaan Partners XI's portfolio value rose 9.2% quarter-over-quarter to $139M.

Based on Canaan Partners XI's 13F filing for Q1 2023, filed 6 Apr 2023.